The goal of personalized medicine is to recommend drug treatment based on an individual's genetic makeup. Pharmacogenomic studies utilize two main approaches: candidate gene and whole-genome. Both approaches analyze genetic variants such as single nucleotide polymorphisms (SNPs) to identify associations with drug response. In addition to DNA sequence variations, nongenetic but heritable epigenetic systems have also been implicated in regulating gene expression that could infl uence drug response. The International HapMap Project lymphoblastoid cell lines (LCLs) have been used to study genetic determinants responsible for expression variation and drug response. Recent studies have demonstrated that common genetic variants, including both SNPs and copy number variants (CNVs) account for a substantial fraction of natural variation in gene expression. Given the critical role played by DNA methylation in gene regulation and the fact that DNA methylation is currently the most studied epigenetic system, we suggest that profi ling the variation in DNA methylation in the HapMap samples will provide new insights into the regulation of gene expression as well as the mechanisms of individual drug response at a new level of complexity. Epigenomics will substantially add to our knowledge of how genetics explains gene expression and pharmacogenomics.
Introduction
Drug response is likely a multi-genic trait with numerous genes playing a role in drug response and toxicity. Scientists are beginning to appreciate the daunting level of complexity in the search for genes associated with drug response and/or toxicity. Predicting which patients will respond or experience an adverse effect would be highly benefi cial to medicine. One reason is that adverse drug reactions (ADRs) have become one of the leading causes of hospitalization and death in the United States, accounting for more than 2.2 million serious cases and over 100,000 deaths a year estimated in a meta-analysis study (Lazarou et al 1998) . Understandably, personalization of medical treatment would help to prevent this by identifying those individuals at greatest risk for toxicity prior to therapy (Ratain 2003 (Ratain , 2007 .
There are several examples of the personalized medical approach, which include genotype-based selection of patients for effective therapy, to spare those who would not respond or would suffer undesirable side effects (Jain 2002) . To fully understand the risk for a given patient, whole-genome data would be most comprehensive; however we are not yet at the point of translating that information into dosing recommendations (Ratain 2007 ). The challenge is that drug response is infl uenced by many different genetic and nongenetic factors and the extent to which each factor contributes to variation in response is not yet fully understood making the development of diagnostic tests that could predict an individual's response to a particular drug diffi cult.
During the past decade or so, equipped with the human whole-genome sequences (Lander et al 2001; Venter et al 2001) and high throughput genotying technologies (eg, sequencing, microarrays) (Dearlove 2002; Twyman 2004; Romkes and Buch 2005) , exciting progress has been made in understanding the contribution of human genetic variations, especially in the form of single nucleotide polymorphisms (SNPs), to how individuals respond to medications, either by changing the pharmacokinetics of drugs or by altering the cellular response to therapeutic agents (Roden et al 2006; Yong et al 2006; Giacomini et al 2007; Hartford and Dolan 2007; Vella and Camilleri 2008; Zhang et al 2008c) . Examples include recent studies using a candidate gene approach (Liu et al 2007; Jarjanazi et al 2008; Rudin et al 2008) or a whole-genome analysis (Huang et al 2007a (Huang et al , 2007b Zhang et al 2008b) to identify genetic variants that are correlated with cytotoxicity to anticancer agents. In addition to SNPs, other genetic elements such as DNA copy number variants (CNVs) have been implicated in drug response (Cappuzzo et al 2005; Greshock et al 2008) . The association studies aim to link genetic variation, either in the form of SNPs or CNVs (both causal or as markers) to expression of targeted gene(s), which in turn may determine, in part, the variation in individual response to drugs. However, not only DNA sequence-based variations (SNPs and CNVs) can affect gene expression, other nongenetic factors such as environment/ habitat (Idaghdour et al 2008) and epigenetic status (Zhang et al 2008d) can also regulate gene expression in vivo, suggesting the potential roles of these nongenetic factors in determining variation in drug response (Figure 1 ). Furthermore, environmental factors have been shown to affect epigenetic status (Wade and Archer 2006) . For example, Kirk and colleagues (2008) reviewed the role of botanicals in epigenetic modulation. The effects of soy foods and exposure to genistein (a soy isofl avone) in breast cancer risk reduction have also been discussed (Warri et al 2008) . Recent studies suggest that epigenetic regulation may in part mediate the complex gene-by-environment interactions that can lead to asthma (Miller and Ho 2008) and other diseases (Edwards and Myers 2007) . Though three mechanisms, including CpG methylation, histone modifi cation and RNA-associated silencing (Beck et al 1999; Holliday 2000; Fazzari and Greally 2004) , have been defi ned as epigenetic modifi ers, this review will focus on DNA methylation at CpG sites, which is currently the most well understood eukaryotic epigenetic modifi cation, due to the availability of high throughput technology such as the Affymetrix ChIP-on-chip (Zhang et al 2006; Affymetrix 2007) , the Illumina BeadArray platform
Phenotypes

Genetic factors
Epigenetic factors Environmental factors DNA methylation and drug response (Bibikova et al 2006; Idaghdour et al 2008) and the Roche NimbleGen arrays (Weber et al 2005) . Methylation at CpG sites can be an accurate proxy for other epigenetic marks, such as histone methylation and acetylation (Lippman et al 2004; Zhang et al 2007b) . DNA methylation can be either de novo (when CpG sites on both DNA strands are unmethylated) or maintenance (when CpG sites on one strand are methylated). Methylation of the C 5 of cytosine residues in DNA has long been recognized as a fundamental epigenetic silencing mechanism (Holliday and Pugh 1975; Holliday 1989) . 5-methylcytosine is also highly mutagenic, causing higher mutation rates at CpG sites for both transitions and transversions (Zhang et al 2007a) . Given the critical role of DNA methylation in regulating gene expression, we suggest that genome-wide profi ling of epigenetic variation (methylome) and association studies using these epigenomic data will provide new insights into gene regulation and individual drug response at a higher level of complexity relative to the current genetic variant-based pharmacogenomic studies. We suggest that the next wave of pharmacogenomic studies will have greater depth if both genetic variants and epigenetic variations are included in the analysis.
Gene expression, drug response, and DNA methylation
Gene expression acts as an intermediate phenotype situated between genetic (eg, sequence variation in DNA) and nongenetic factors (eg, environmental stimuli) and other more complex cellular, tissue, organ or whole-organism phenotypes (eg, drug response). Numerous studies have shown that gene expression can affect susceptibility to drug response. For instance, a widely appreciated example is the multi-drug resistance exhibited by tumor cells to anticancer agents through over-expression of MDR genes (Perez-Tomas 2006) . Numerous recent studies have demonstrated the use of genomic data, particularly gene expression signatures, as clinical prognostic factors in cancer and other complex diseases (Garman et al 2007; Nevins and Potti 2007) . These studies have demonstrated that gene expression signatures have the capability of predicting response to various commonly used and newly developing cancer therapeutics (Potti and Nevins 2008) . For example, a recent study showed that incorporation of gene expression signatures into clinical risk stratifi cation can refi ne prognosis in breast cancer (Acharya et al 2008) .
On one hand, quantitative variation in gene-expression level (eg, mRNA transcript abundance) as a complex trait is heritable and has been mapped to the human genome as expression quantitative trait loci (eQTLs) in LCLs including the HapMap samples (Morley et al 2004; Spielman et al 2007; Stranger et al 2007b; Duan et al 2008; Zhang et al 2008a) , which represent genomic regions marked by cis-acting or trans-acting SNPs for the genetic control of gene expression. Substantial contribution of DNA structural variation (eg, CNVs) (Redon et al 2006) to gene expression variation has also been demonstrated recently in the HapMap samples (Stranger et al 2007a) , which include 210 individuals of major world populations in northern and western Europe (CEU, Caucasians from Utah, USA), Africa (YRI, Yoruba people from Ibadan, Nigeria) and Asia (JPT, Japanese from Tokyo, Japan; CHB, Han Chinese from Beijing, China) (Zhang et al 2008c) . On the other hand, increased methylation in the promoter region of a gene has been shown to lead to reduced expression, whereas methylation in the transcribed region has a variable effect on gene expression (Jones 1999; Singal et al 2002) . Thus DNA methylation patterns, together with SNPs or CNVs, likely play an important role in gene regulation, which in turn may affect drug response.
Integrating genetic variation, expression and sensitivity to drugs has been a focus of several recent studies. Both candidate gene approach (Liu et al 2007; Jarjanazi et al 2008; Rudin et al 2008) or whole-genome associations (Huang et al 2007a (Huang et al , 2007b Zhang et al 2008b) have been employed to identify genetic variants that are associated with both drug-induced cytotoxicity and gene expression. These studies did not integrate promoter methylation; however epigenetic regulation of gene expression could explain much of the variation that is not due to SNPs or CNVs and improve our understanding of the role of gene expression in drug response.
Though the roles of DNA methylation in diseases such as cancer have been a topic of considerable interest in the past few years (Das and Singal 2004; Egger et al 2004; Shames et al 2007; Vucic et al 2008) , the relationship between variation in DNA methylation status and gene expression has just begun to be studied. In a pilot study of the Human Epigenome Project (Bradbury 2003) , DNA methylation profi ling (∼1.9 million CpG sites) of human chromosomes 6, 20 and 22 from 12 different tissues was performed (Eckhardt et al 2006) . A substantial fraction (∼17%) of genes were found differentially methylated in their 5' UTRs and about one-third of the differentially methylated 5' UTRs were inversely correlated with transcription even after controlling for factors reported to affect DNA methylation such as sex and age (Eckhardt et al 2006) .
In the past few years, the roles of DNA methylation through regulating gene expression in drug response have also been investigated by various laboratories (Gius et al 2005; Brown and Glasspool 2007; Strathdee 2007) . One example is the DNA repair enzyme O 6 -methylguanine DNA methyltransferase (MGMT ) effi ciency of which has been associated with an increased susceptibility to alkylating agent toxicity (Kaina et al 1998; Gerson 2004; Rabik et al 2006) . MGMT is transcriptionally silenced by promoter hypermethylation in several human cancers such as diffuse large B-cell lymphoma (Esteller et al 2002) as well as head and neck squamous cell carcinoma (Zuo et al 2004) . In a retrospective cohort study, Esteller and colleagues (2002) demonstrated that MGMT promoter hypermethylation appeared to be a useful marker for predicting survival in patients with diffuse large B-cell lymphoma treated with multidrug regimens including cyclophosphamide. The demethylation of MGMT promoter was also shown to be involved in basic fi broblast growth factor-induced resistance against temozolomide in human melanoma cells (Fontijn et al 2007) . More recently, Shen and colleagues (2007) assessed DNA methylation of 32 promoter-associated CpG islands in human cancer cell lines from the National Cancer Institute (NCI) drugscreening panel (NCI-60 panel). By correlating drug activity with DNA methylation, they identifi ed a list of methylation markers that predicted sensitivity to chemotherapeutic drugs. For example, hypermethylation of the TP53 homologue TP73 and associated gene silencing was strongly correlated with sensitivity to alkylating agents. The methylation status of tumor suppressor genes (TIMP3, APC, and IGSF4) in the NCI-60 panel has also been found signifi cantly correlated with the sensitivity to some antimetabolites such as fl uorouracil (5-FU) (Sasaki et al 2008) . In another study, Grovdal and colleagues (2007) showed a signifi cant effect of methylation status of P15, CDH (E-cadherin) and HIC (hypermethylated in cancer 1) genes on the outcome of conventional chemotherapy in high-risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia following MDS. Though the current studies using patients or patient-derived cell lines (eg, the NCI-60 panel) have shown the potential roles of DNA methylation of some candidate genes in drug response and cytotoxicity, the relationship between DNA methylation status of genes (not only candidate genes like tumor suppressors or MGMT) with drug resistance or sensitivity have not been comprehensively investigated.
Overall, these studies suggest that the variation in DNA methylation status can signifi cantly contribute to the variation in gene expression, which in turn may affect drug response. Figure 2 shows a possible scenario for the relationship between DNA methylation and gene expression as well as drug response in a population. Similar to other genetic factors, cytosine methylation patterns are also heritable through cell division. Their preservation involves the "maintenance" methyltransferase DNMT1, which has specifi city for hemi-methylated CpG dinucleotides; the enzyme thus can methylate CpGs in a newly synthesized DNA strand based on the presence of methylation in the CpG dinucleotide in the complementary template strand (Bernstein et al 2007) . Therefore, this kind of epigenetic inheritance may allow cells of different phenotype (eg, drug response) but identical genotype to transmit their phenotype to their offspring. Although many genes have been identifi ed that acquire methylation and whose expression is methylation-sensitive, little is known about how DNA methylation is controlled (Yoon et al 2002) . Our current knowledge suggest DNA methylation may be regulated by different variants of DNA methyltransferase (Wang et al 2007) or RASGRF1 (a Ras protein-specifi c guanine nucleotide-releasing factor 1) (Yoon et al 2002) . At present we have very poor understanding of the factors that contribute to interindividual epigenetic variation. The effects of DNA methylation status on gene regulation can be independent of those based on genetic variations (eg, SNPs), suggesting that the availability of a high-resolution DNA methylation resource could add another layer of information to our understanding of how genetic and epigenetic variation could be used in pharmacogenomic studies.
Whole-genome approaches to profi ling DNA methylation
Recent progress in biotechnology has provided tools to detect DNA methylation in the human genome, thus potentially allowing the study of the roles of DNA methylation in gene regulation. DNA methylation can be detected using bisulfi te conversion, methylation-sensitive restriction enzyme (MSRE) digestion, methyl-binding proteins and antimethylcytosine antibodies. Combining these techniques with DNA microarrays and high-throughput sequencing has made the mapping of DNA methylation feasible on a genome-wide scale (Zilberman and Henikoff 2007) .
Bisulfi te conversion is based on treatment of DNA with bisulfi te, a chemical that results in the conversion of cytosine to uracil, but leaves 5-methylcytosine residues unaffected, thus introducing specifi c changes (C to T transitions) in the DNA sequence that depend on the methylation status of cytosine residues. The methylation status then DNA methylation and drug response can be deduced by techniques such as direct sequencing (Frommer et al 1992; Eckhardt et al 2006) , pyrosequencing (Colella et al 2003) or microarray-based methods (Abecasis et al 2000) , which can be used in a genome-wide analysis of DNA methylation. For the latter, microarrays can be designed using oligonucleotide pairs targeting CpG sites of interest, with one complementary to the unaltered methylated sequence, and the other to the C-to-T converted unmethylated sequence (Adorjan et al 2002) . As the name implies, the method of MSRE digestion uses methylation specifi c restriction enzymes such as HpaII to cleave DNA at specifi c methylated-cytosine residues. Similarly, wholegenome oligonucleotide microarrays then can be used to differentiate the MSRE-digested products and background (eg, DNA fragments digested by nonmethylation-sensitive restriction enzymes such as MspI) (Zhang et al 2008d) . In contrast, the methods based on methyl-binding proteins and anti-methylcytosine antibodies use specifi c methyl-group binding proteins or methylcytosine antibodies to enrich methylated DNA fragments through chromatin immunoprecipitation (ChIP) (Zhang et al 2006) . Again, whole-genome oligonucleotide microarrays can be used to analyze the methylation status of the ChIP products.
In spite of some limitations, for example, the coverage of the MSRE digestion approach is limited to the CpG sites (Zhang et al 2008d) ; and incomplete conversion and degradation of DNA during bisulfi te treatment could be confounding factors for the bisulfi te conversion approach (Grunau et al 2001) . These approaches have begun to allow genome-wide analyses of DNA methylation in humans (Eckhardt et al 2006) . For example, in a previously mentioned study, using the bisulfi te sequencing approach, the CpG methylation profi les of 43 samples derived from 12 different human tissues (eg, heart muscle, skeletal muscle) and various primary cell types (eg, dermal fi broblasts, CD4+ and CD8+ lymphocytes) were determined for chromosomes 6, 20, and 22 (Eckhardt et al 2006) . Obviously, these whole-genome or epigenomic approaches provide promising tools to profi le the variation in DNA methylation as well as to illustrate the relationship between DNA methylation and gene expression.
Conclusions and outlook
The realization of personalized medicine promises better treatment regimens for individuals based on the information contained in the human genome. To date, most pharmacogenomic studies have focused on the contribution of common genetic variants (SNPs and CNVs) to individual response to therapeutic treatments. However, nongenetic factors such as the epigenetic systems could also play an important role in gene regulation, which in turn could affect drug response. DNA methylation is currently the best-understood epigenetic system (Fazzari and Greally 2004) . In the past few years, whole-genome DNA methylation profiling has become possible benefi ting from the combination of methylation-specifi c and microarray-based techniques. Given the fact that common genetic variants only account for a fraction of the variation in drug response, other mechanisms such as DNA methylation status could help explain the remaining variation in drug response. We envision that in an ideal world, treatment decisions would be based on an individual's whole-genome information which includes both genetic and nongenetic factors including DNA methylation status. A more comprehensive view of the genome that includes epigenetic information will also provide information on the use of agents aimed at pathways important in DNA methylation and gene regulation (Plimack et al 2007) .
Research efforts such as the Human Epigenome Project, which aims to identify, catalog and interpret genome-wide DNA methylation profi les of all human genes in all major tissues (Bradbury 2003; Rakyan et al 2004; Eckhardt et al 2006) , no doubt will provide new insights into the epigenetic components of the human genome and tissue specifi city of epigenetic regulation of expression. However, integration of epigenomic profi ling with resources such as those provided by the International HapMap Project (HapMap 2003 (HapMap , 2005 , which has genotypic data and various publicly available phenotypes that include gene expression (see the Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/), drug response (see http://www.PharmGKB.org) on a panel of LCLs derived from major world populations (Zhang et al 2008c) , will greatly facilitate the identifi cation of both genetic and nongenetic determinants responsible for the response to therapeutic treatments. The HapMap LCLs have been used to build cell-based models for pharmacogenomic discovery but currently lacks epigenomic information. This information could be integrated with publicly available genotypic, gene expression and drug sensitivity data on the same cell line (Zhang and Dolan 2008) . Additional tissues including the liver or skin should be considered for pharmacogenomic discovery by integrating genomic, epigenomic, expression and drug metabolism data. These models could be of great value to the pharmacogenomic community.
